Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population - PubMed (original) (raw)
Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population
Xiaoyan Song et al. Infect Control Hosp Epidemiol. 2008 Sep.
Abstract
Background: Clostridium difficile-associated disease (CDAD) is responsible for increased morbidity and a substantial economic burden. Incidences of CDAD, including those with a severe course of illness, have been increasing rapidly.
Objective: To evaluate the excess mortality, increased length of stay (LOS) in the hospital, and additional costs associated with CDAD.
Design: A retrospective matched cohort study.
Patients: Adult patients admitted to a large tertiary care hospital between January 2000 and October 2005.
Methods: Adult patients were tested with a C. difficile laboratory assay at admission or 72 hours after admission. Infected patients had 1 or more positive assay results and were individually matched to 1 uninfected patient who had negative assay results, by exposure time, age, ward, and at least 2 measurements for comorbidity and severity of illness.
Results: The incidence rate of CDAD among adult patients increased from 0.57 cases per 1,000 patient-days at risk before 2004 to 0.88 cases per 1,000 patient-days at risk after 2004 (P < .001). The 630 infected patients had a mortality rate of 11.9%; the 630 uninfected patients had a mortality rate of 15.1% (P = .02). After adjustment in the multivariate analysis, we found that the LOS for infected patients was 4 days longer than that for uninfected patients (P < .001). If CDAD occurred after 2004, the additional LOS increased to 5.5 days. The direct cost associated with CDAD was 306percase;afteryear2004,itincreasedto306 per case; after year 2004, it increased to 306percase;afteryear2004,itincreasedto6,326 per case.
Conclusions: There may be no excess mortality among patients with CDAD, compared with patients without it, but the economic burden of CDAD is increasing. By 2004, CDAD-associated medical expenditures approached $1,000,000 per year at our institution alone.
Comment in
- Commentary: preventing Clostridium difficile-associated disease: is it time to pay the piper?
Perencevich EN, Thom KA. Perencevich EN, et al. Infect Control Hosp Epidemiol. 2008 Sep;29(9):829-31. doi: 10.1086/591058. Infect Control Hosp Epidemiol. 2008. PMID: 18643747 No abstract available.
Similar articles
- Costs of nosocomial Clostridium difficile-associated diarrhoea.
Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. Vonberg RP, et al. J Hosp Infect. 2008 Sep;70(1):15-20. doi: 10.1016/j.jhin.2008.05.004. Epub 2008 Jul 7. J Hosp Infect. 2008. PMID: 18602185 - Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients.
Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Dubberke ER, et al. Clin Infect Dis. 2008 Feb 15;46(4):497-504. doi: 10.1086/526530. Clin Infect Dis. 2008. PMID: 18197759 - Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals.
Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M; Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance Program. Miller MA, et al. Infect Control Hosp Epidemiol. 2002 Mar;23(3):137-40. doi: 10.1086/502023. Infect Control Hosp Epidemiol. 2002. PMID: 11918118 - [The problem of Clostridium dlfficile infection in children with inflammatory bowel disease].
Akutko K, Iwańczak B. Akutko K, et al. Pol Merkur Lekarski. 2013 Dec;35(210):385-90. Pol Merkur Lekarski. 2013. PMID: 24490471 Review. Polish. - Emergence of Clostridium difficile-associated disease in North America and Europe.
Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Kuijper EJ, et al. Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18. doi: 10.1111/j.1469-0691.2006.01580.x. Clin Microbiol Infect. 2006. PMID: 16965399 Review.
Cited by
- Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.
Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Zhang S, et al. BMC Infect Dis. 2016 Aug 25;16(1):447. doi: 10.1186/s12879-016-1786-6. BMC Infect Dis. 2016. PMID: 27562241 Free PMC article. Review. - Prevalence and management of antibiotic associated diarrhea in general hospitals.
Elseviers MM, Van Camp Y, Nayaert S, Duré K, Annemans L, Tanghe A, Vermeersch S. Elseviers MM, et al. BMC Infect Dis. 2015 Mar 17;15:129. doi: 10.1186/s12879-015-0869-0. BMC Infect Dis. 2015. PMID: 25888351 Free PMC article. - Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.
Fukuda H, Yano T, Shimono N. Fukuda H, et al. Pharmacoeconomics. 2018 Nov;36(11):1367-1376. doi: 10.1007/s40273-018-0692-8. Pharmacoeconomics. 2018. PMID: 30022364 - Hospital Clostridium difficile infection (CDI) incidence as a risk factor for hospital-associated CDI.
Miller AC, Polgreen LA, Cavanaugh JE, Polgreen PM. Miller AC, et al. Am J Infect Control. 2016 Jul 1;44(7):825-9. doi: 10.1016/j.ajic.2016.01.006. Epub 2016 Mar 2. Am J Infect Control. 2016. PMID: 26944007 Free PMC article. - Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention.
Claeys KC, Hopkins TL, Vega AD, Heil EL. Claeys KC, et al. Curr Infect Dis Rep. 2018 Mar 23;20(5):7. doi: 10.1007/s11908-018-0615-z. Curr Infect Dis Rep. 2018. PMID: 29572691 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical